Company research
Zomedica Corp.
CIK 1684144Updated Sep 25, 2026
SecurityZOMDF · OTC · equity
Name history
Zomedica Pharmaceuticals Corp. · through Sep 28, 2020
ZOMDF price & chart
Loading TradingView…
OTC:ZOMDF on TradingView ↗About the company
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop® line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian PLUSTM Zero Touch® monitoring system and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 17% in 2025 to $32 million and maintains a strong balance sheet with approximately $44 million in liquidity as of June 30, 2026. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pet…
In the news
No coverage from other publishers is available.
Recent filings
4 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 127,039,000Source | 207,360,000Source | 253,197,000Source | 279,610,000Source |
| Property, Plant and Equipment, NetUSD | 20,912,000Source | 24,589,000Source | 10,347,000Source | 6,809,000Source |
| GoodwillUSD | 0Source | 45,556,000Source | 61,580,000Source | 63,979,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 38,808,000Source | 52,538,000Source | 55,364,000Source | 41,799,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 9,017,000Source | 7,021,000Source | 12,952,000Source | 27,399,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,012,000Source | 2,423,000Source | 1,197,000Source | 596,000Source |
| Inventory, NetUSD | 5,545,000Source | 5,058,000Source | 5,123,000Source | 2,746,000Source |
| Assets, CurrentUSD | 64,043,000Source | 81,773,000Source | 99,882,000Source | 123,501,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,787,000Source | 2,291,000Source | 2,064,000Source | 3,799,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,023,000Source | 1,611,000Source | 2,466,000Source | 1,665,000Source |
| Other Assets, NoncurrentUSD | 1,101,000Source | 1,100,000Source | 822,000Source | 265,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 11,642,000Source | 11,696,000Source | 13,180,000Source | 12,218,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 380,973,000Source | 380,973,000Source | 380,973,000Source | 380,973,000Source |
| Retained Earnings (Accumulated Deficit)USD | -299,773,000Source | -217,915,000Source | -170,933,000Source | -136,404,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 160,000Source | 88,000Source | 48,000Source | -843,000Source |
| Stockholders' Equity Attributable to ParentUSD | 115,397,000Source | 195,664,000Source | 240,017,000Source | 267,392,000Source |
| Additional Paid in Capital, Common StockUSD | 34,037,000Source | 32,518,000Source | 29,929,000Source | 23,666,000Source |
| Liabilities and EquityUSD | 127,039,000Source | 207,360,000Source | 253,197,000Source | 279,610,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,449,000Source | 9,331,000Source | 9,032,000Source | 7,811,000Source |
| Operating Lease, Liability, CurrentUSD | 717,000Source | 523,000Source | 916,000Source | 641,000Source |
| Accounts Payable, CurrentUSD | 1,718,000Source | 1,929,000Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 1,467,000Source | 1,291,000Source | 1,814,000Source | 1,097,000Source |
| Deferred Income Tax Liabilities, NetUSD | 27,000Source | 456,000Source | 1,138,000Source | 1,245,000Source |
| Other Liabilities, NoncurrentUSD | 467,000Source | 399,000Source | 944,000Source | 1,883,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 6,394,000Source | 6,431,000Source | — | — |
| Deferred Tax Liabilities, NetUSD | 27,000Source | 456,000Source | 1,138,000Source | 1,245,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,472,000Source | 2,778,000Source | 6,263,000Source | 7,891,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 590,000Source | 1,227,000Source | 617,000Source | 283,000Source |
| Increase (Decrease) in InventoriesUSD | 548,000Source | 205,000Source | 1,059,000Source | 4,008,000Source |
| Increase (Decrease) in Accounts PayableUSD | -90,000Source | -200,000Source | — | — |
| Deferred Income Tax Expense (Benefit)USD | -428,000Source | -682,000Source | -1,489,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -17,649,000Source | -23,630,000Source | -15,975,000Source | -11,670,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | 23,959,000Source | 24,304,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 19,575,000Source | 17,854,000Source | 1,577,000Source | -155,880,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 567,000Source | 5,212,000Source | 496,000Source | 787,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | -70,000Source | — | 8,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 9,017,000Source | 7,021,000Source | 12,952,000Source | 27,399,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 153,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 6,263,000Source | 7,891,000Source |
| Amortization of Intangible AssetsUSD | 5,896,000Source | 6,441,000Source | 5,468,000Source | 3,616,000Source |
| DepreciationUSD | 2,055,000Source | 1,545,000Source | 830,000Source | 426,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -6,000Source | -252,000Source | 28,000Source | -152,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -68,000Source | -210,000Source | 24,000Source | 1,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -68,000Source | -210,000Source | 24,000Source | 1,000Source |
| General and Administrative ExpenseUSD | 24,496,000Source | 29,656,000Source | 29,029,000Source | — |
| GoodwillUSD | 0Source | 45,556,000Source | 61,580,000Source | 63,979,000Source |
| Goodwill, Impairment LossUSD | 45,556,000Source | 16,024,000Source | 12,195,000Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | 0Source | — | — |
| Income (Loss) from Equity Method InvestmentsUSD | -141,000Source | -159,000Source | — | — |
| Income Tax Expense (Benefit)USD | -278,000Source | -557,000Source | -1,331,000Source | -2,366,000Source |
| Net Income (Loss) Attributable to ParentUSD | -81,858,000Source | -46,982,000Source | -34,529,000Source | -17,015,000Source |
| Operating Lease, ExpenseUSD | 1,113,000Source | 1,312,000Source | 1,203,000Source | 661,000Source |
| Other Nonoperating Income (Expense)USD | -144,000Source | 10,000Source | 2,080,000Source | -7,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 32,030,000Source | 27,285,000Source | 25,186,000Source | 18,930,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | 32,997,000Source |
| Operating Income (Loss)USD | -84,353,000Source | -51,053,000Source | -31,592,000Source | -21,923,000Source |
| Other Nonoperating Income (Expense)USD | -144,000Source | 10,000Source | 2,080,000Source | -7,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -82,136,000Source | -47,539,000Source | -35,860,000Source | -19,381,000Source |
| Income Tax Expense (Benefit)USD | -278,000Source | -557,000Source | -1,331,000Source | -2,366,000Source |
| Net Income (Loss) Attributable to ParentUSD | -81,858,000Source | -46,982,000Source | -34,529,000Source | -17,015,000Source |
| Earnings Per Share, BasicUSD per share | -0.08Source | -0.05Source | -0.04Source | — |
| Earnings Per Share, DilutedUSD per share | -0.08Source | -0.05Source | -0.04Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 979,949,668Source | 979,949,668Source | 979,949,668Source | 979,924,052Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 979,949,668Source | 979,949,668Source | 979,949,668Source | 979,924,052Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 5,896,000Source | 6,441,000Source | 5,468,000Source | 3,616,000Source |
| Current Income Tax Expense (Benefit)USD | 150,000Source | 125,000Source | 158,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -6,000Source | -252,000Source | 28,000Source | -152,000Source |
| General and Administrative ExpenseUSD | 24,496,000Source | 29,656,000Source | 29,029,000Source | — |
| Goodwill, Impairment LossUSD | 45,556,000Source | 16,024,000Source | 12,195,000Source | — |
| Gross ProfitUSD | 21,679,000Source | 19,087,000Source | 17,318,000Source | 13,652,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -82,889,000Source | -48,380,000Source | -36,954,000Source | — |
| Income (Loss) from Equity Method InvestmentsUSD | -141,000Source | -159,000Source | — | — |
| Interest ExpenseUSD | — | — | 175,000Source | 1,000Source |
| Investment Income, NetUSD | 2,435,000Source | 3,966,000Source | 5,458,000Source | — |
| Operating Lease, ExpenseUSD | 1,113,000Source | 1,312,000Source | 1,203,000Source | 661,000Source |
| Research and Development ExpenseUSD | 7,166,000Source | 7,268,000Source | 5,744,000Source | 2,578,000Source |
| Selling and Marketing ExpenseUSD | 18,537,000Source | 17,192,000Source | 14,137,000Source | — |
Filing attachments
zom_ex991.htm · 8-K · 2026-08-05
EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity Zomedica surpasses $9 million in second quarter revenue for the first time while extending its record of consecutive year-over-year revenue growth to 22 quarters. ANN ARBOR, MI / ACCESSWIRE / August 5, 2026 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), an animal heal…
Read attachment ↗zom_ex991.htm · 8-K · 2026-05-06
EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity Zomedica surpasses $8 million in first quarter revenue for the first time and delivers record year-over-year revenue for 21 st straight quarter. ANN ARBOR, MI / ACCESSWIRE / May 6, 2026 / Zomedica Corp. (OTCQB: ZOMDF) (“Zomedica” or the “Company”), an animal health company offering innovative point-o…
Read attachment ↗zom_ex991.htm · 8-K · 2026-03-16
EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Fourth Quarter Revenue of $10.5 Million and Full Year Revenue of $32.0 Million for 2025, Reflecting 17% Annual Growth; Achieves 68% Gross Margin and Maintains $53.3 Million in Liquidity Zomedica surpasses $10 million in quarterly revenue for the first time and delivers record year-over-year revenue for 20 th straight quarter. ANN ARBOR, MI / ACCESSWIRE / March 16, 2026 / Zomedica Corp. (OTCQB: ZOMD…
Read attachment ↗zom_ex991.htm · 8-K · 2025-11-04
EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth Zomedica posts highest quarterly revenue ever and record year-over-year revenue for 19 th straight quarter! ANN ARBOR, MI / ACCESSWIRE / November 4, 2025 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), an animal health company offering point-of-care diag…
Read attachment ↗zom_ex991.htm · 8-K · 2025-08-06
EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Second Quarter 2025 Financial Results: Revenue up 14% to $7 Million with 67% Gross Margins and $59 Million in Liquidity to Support Growth Zomedica posts record year-over-year revenue for 18 th straight quarter! ANN ARBOR, MI / ACCESSWIRE / August 6, 2025 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for…
Read attachment ↗zom_ex991.htm · 8-K · 2025-05-15
EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth ANN ARBOR, MI / ACCESSWIRE / May 15, 2025 / Zomedica Corp. (OTCQB: ZOMDF) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the f…
Read attachment ↗